Market Closed -
Other stock markets
|
After market 03:59:56 pm | |||
0.879 EUR | -1.79% | 0.886 | +0.80% |
07:00am | Pharming Group N.V. Provides Revenue Guidance for 2024 | CI |
07:00am | Pharming Group N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 989.6 | 811.6 | 502.8 | 707.2 | 690.2 | 602.7 | - | - |
Enterprise Value (EV) 1 | 975.2 | 765.7 | 457.1 | 637.6 | 619.7 | 511.9 | 483.3 | 451.3 |
P/E ratio | 29 x | 26.5 x | 37.1 x | - | -74.7 x | -298 x | 40.7 x | 10.5 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 5.85 x | 4.37 x | 2.78 x | 3.62 x | 3.08 x | 2.29 x | 2 x | 1.74 x |
EV / Revenue | 5.77 x | 4.12 x | 2.53 x | 3.27 x | 2.76 x | 1.94 x | 1.6 x | 1.3 x |
EV / EBITDA | 14.8 x | 10.1 x | 8.9 x | 21.4 x | 64.4 x | 50.4 x | 15.9 x | 6.51 x |
EV / FCF | 24.1 x | 12.4 x | 21.5 x | 24.4 x | -35.9 x | 20.7 x | 14.5 x | 7.84 x |
FCF Yield | 4.14% | 8.09% | 4.66% | 4.1% | -2.78% | 4.83% | 6.92% | 12.7% |
Price to Book | 9.45 x | 5.55 x | - | - | 3.44 x | - | - | - |
Nbr of stocks (in thousands) | 631,323 | 638,056 | 648,749 | 652,414 | 669,406 | 673,438 | - | - |
Reference price 2 | 1.568 | 1.272 | 0.7750 | 1.084 | 1.031 | 0.8950 | 0.8950 | 0.8950 |
Announcement Date | 3/5/20 | 3/4/21 | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 169 | 185.7 | 180.7 | 195.1 | 224.1 | 263.3 | 302 | 346.5 |
EBITDA 1 | 66.08 | 75.74 | 51.35 | 29.82 | 9.629 | 10.15 | 30.44 | 69.28 |
EBIT 1 | 60.91 | 67.42 | 33.53 | 17.3 | -4.922 | -7.243 | 6.381 | 38.24 |
Operating Margin | 36.03% | 36.31% | 18.55% | 8.87% | -2.2% | -2.75% | 2.11% | 11.04% |
Earnings before Tax (EBT) 1 | 46.68 | 39.27 | 20.97 | 14.22 | -10.98 | 3.38 | 18.89 | 51.99 |
Net income 1 | 36.2 | 32.65 | 14.54 | 12.98 | -9.246 | 1.268 | 14.05 | 41.31 |
Net margin | 21.41% | 17.58% | 8.04% | 6.65% | -4.12% | 0.48% | 4.65% | 11.92% |
EPS 2 | 0.0540 | 0.0480 | 0.0209 | - | -0.0138 | -0.003000 | 0.0220 | 0.0850 |
Free Cash Flow 1 | 40.38 | 61.96 | 21.29 | 26.17 | -17.25 | 24.75 | 33.42 | 57.53 |
FCF margin | 23.89% | 33.37% | 11.78% | 13.41% | -7.7% | 9.4% | 11.07% | 16.6% |
FCF Conversion (EBITDA) | 61.11% | 81.82% | 41.45% | 87.76% | - | 243.85% | 109.81% | 83.04% |
FCF Conversion (Net income) | 111.57% | 189.76% | 146.44% | 201.67% | - | 1,951.07% | 237.83% | 139.26% |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/5/20 | 3/4/21 | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2020 S1 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 88.59 | 78.74 | 45.62 | 62.43 | 44.22 | 49.02 | 94.59 | 53.87 | 51.84 | 38.75 | 50.2 | 89.1 | 63 | 74.19 | 51.72 | 67.41 | 67.41 | 67.55 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | - | - | 9.74 | 7.613 | - | 17.42 | - | 7.712 | -9.658 | -12.45 | 4.845 | - | 1.795 | 1.005 | 1.917 | -2.029 | 55.95 | -72.05 |
Operating Margin | - | - | 21.35% | 12.19% | - | 35.54% | - | 14.31% | -18.63% | -32.12% | 9.65% | - | 2.85% | 1.35% | 2.92% | -3.01% | 83% | -106.67% |
Earnings before Tax (EBT) 1 | 25.9 | 16.91 | 1.14 | 3.583 | 4.015 | 19.12 | 23.25 | 9.217 | -17.16 | -15.19 | 3.096 | -12.15 | 3.117 | -1.827 | -15.47 | -0.743 | 57.24 | -70.77 |
Net income 1 | 18.14 | 12.12 | -0.3616 | 3.213 | 3.283 | 15.35 | 18.77 | 9.04 | -13.88 | -11.12 | 1.206 | -9.957 | 3.306 | -2.467 | -11.58 | -0.743 | 57.24 | -70.77 |
Net margin | 20.48% | 15.39% | -0.79% | 5.15% | 7.42% | 31.31% | 19.85% | 16.78% | -26.78% | -28.7% | 2.4% | -11.18% | 5.25% | -3.33% | -22.39% | -1.1% | 84.91% | -104.77% |
EPS | 0.0250 | 0.0160 | -0.000860 | - | - | - | - | 0.0129 | - | - | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 7/30/20 | 8/5/21 | 10/28/21 | 3/17/22 | 5/12/22 | 8/4/22 | 8/4/22 | 10/27/22 | 3/16/23 | 5/11/23 | 8/3/23 | 8/3/23 | 10/26/23 | 3/14/24 | 5/8/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 14.4 | 46 | 45.6 | 69.7 | 70.5 | 90.9 | 119 | 151 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | 40.4 | 62 | 21.3 | 26.2 | -17.3 | 24.7 | 33.4 | 57.5 |
ROE (net income / shareholders' equity) | 43.5% | 26% | - | - | -4.98% | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | 0.1700 | 0.2300 | - | - | 0.3000 | - | - | - |
Cash Flow per Share | 0.1100 | 0.1100 | - | - | - | - | - | - |
Capex 1 | 2.36 | 12 | 12.8 | 1.86 | 1.32 | 4.99 | 5.23 | 5.54 |
Capex / Sales | 1.4% | 6.46% | 7.06% | 0.95% | 0.59% | 1.86% | 1.7% | 1.56% |
Announcement Date | 3/5/20 | 3/4/21 | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.74% | 650M | |
+33.13% | 700B | |
-4.93% | 358B | |
+18.95% | 330B | |
+3.49% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.15% | 161B | |
-1.86% | 157B |
- Stock Market
- Equities
- PHARM Stock
- Financials Pharming Group N.V.